Spondyloarthritis & psoriatic arthritis
Efficacy of risankizumab across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
Authors' conclusion
Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all GRAPPA disease domains and related conditions.
Study context
- Population
- Adults with psoriatic arthritis (PsA) in the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials412/483 and 181/224 completed to week 100
- Outcome
- Efficacy across GRAPPA domains (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions (IBD, uveitis)
- Follow-up
- 100 weeks
Methodological detailsnon-responder imputation, mixed-effect model for repeated measures
- Non-responder imputation
- Mixed-effect model for repeated measures
Pooled result
As reported in the abstract
Efficacy across GRAPPA domains
- Efficacy across all GRAPPA-defined domains, incl. swollen and tender joint counts, enthesitis, dactylitis, skin and nail outcomes, and axial disease
Further pooled results
DAPSA low disease activity (KEEPsAKE 1) · week 100
- Patients achieving DAPSA low disease activity
- 42.4%
MCID in pain (KEEPsAKE 1) · week 100
- Patients reaching MCID in pain
- 62.9%
Safety
New onset or flare of inflammatory bowel disease (IBD) and uveitis · 100 weeks
- Rates of new onset or flare of IBD and uveitis were low
Original publication
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open. Published 25 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →